Several brokerage firms have enlisted LMAT to produce a revenue statement of $35.96 for this quarter- according to reports. Zacks Investment has claimed that three of the research analysts have already issued their estimates on the earnings of this company. The lowest estimate was fixed at $35.90 million, while the highest came in at $36.07 million. LeMaitre Vascular did report a revenue statement of about $30.17 million the previous year, which is indicative of a positive growth rate of about 19.2%. The company will be updating its next earnings report on the 4th of February.
The Quarterly Earnings of LMAT
The stocks of LMAT did issue their previous results on the 29th of October. The company had an EPS of around $0.37 for that quarter, which was quite above the EPS estimated by consensus. The medical supplies also have a 15.41% net margin rate, and a 12.32% return on its equity. The revenue earned by the company was $36.42 million for the previous quarter, which was more than the consensus estimate.
There have been quite a number of research equities that have commented on the stocks of LMAT. Roth Capital has been the first one to set the ball rolling with a price target of $36 on the stock, along with a rating of neutral. This was then issued in a note on the 30th of October. Barrington Research also went down the same rabbit hole with a price target increased to $36, along with a rating of outperform. In the end, Zacks Investment Research joined in the fray with a rating of hold, after it had previously issued a rating of strong buy.
As records say, four of the investment analysts involved in the firm have given it a rating of hold, while three have issued a rating of buy on LMAT. LeMaitre Vascular currently has a Hold rating, with a $35.86 price objective.
